Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil
A biotechnologist in a lab suit studying a syringe with a mesenchymal lineage cells inside.
Furthermore, Mesoblast Limited (NASDAQ:MESO) possesses biologic exclusivity preventing another sponsor from referencing the Ryoncil® biologic license application (BLA) till December 2036, 12 years from the 1st approval, preventing market entry by the biosimilar. Apart from such statutory exclusivities, Mesoblast Limited (NASDAQ:MESO) possesses a robust US intellectual property position on MSC composition of matter, manufacturing, and indications, including SR-aGvHD, which offers a commercial barrier to entry against the competitors through 2044.
While we acknowledge the potential of MESO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MESO and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
14 minutes ago
- Bloomberg
Powell's Last Stand at Jackson Hole
To get John Authers' newsletter delivered directly to your inbox, sign up here. As the world's central bankers gather in Jackson Hole, Wyoming, for their annual dose of fresh air in the shadow of the Tetons, they cansense the plates beneath them are beginning to shift. This will definitely be Jerome Powell's last symposium as chairman of the Federal Reserve, his Last Stand in the Wild West. The drama surrounding his replacement threatens to become all-consuming. Profound changes for the Fed, to be imposed by others, are on the agenda.
Yahoo
41 minutes ago
- Yahoo
Evercore Highlights Amazon (AMZN) Grocery Strategy and Prime Stickiness
Inc. (NASDAQ:AMZN) ranks among the . Evercore ISI highlighted Inc. (NASDAQ:AMZN)'s strategic actions in the grocery industry on August 13, reaffirming its Outperform rating and $280 price target on the company. The firm noted that by strengthening customer engagement through a high-frequency purchase category, Amazon's tighter integration of groceries into the Prime ecosystem raises customer lifetime value and stickiness. Amazon's $25 free delivery threshold, according to Evercore ISI, puts pressure on rivals like Walmart and Instacart to lower their prices. The approach is in line with Amazon's previously declared $4 billion commitment to use the country's current logistics infrastructure to extend its same-day and next-day delivery network to over 4,000 smaller and rural U.S. communities by 2026. According to Evercore's 13th Annual Amazon Survey, Prime Same-Day delivery multiplies the frequency of purchases, the expansion of categories, and the total amount spent by customers on Inc. (NASDAQ:AMZN). The firm refers to this as 'Shipping Elasticity', which suggests that faster shipping results in more frequent and larger purchases. Inc. (NASDAQ:AMZN), is an American multinational technology company that offers a wide range of commercial interests that include digital streaming, online advertising, e-commerce, cloud computing through Amazon Web Services (AWS), and artificial intelligence. While we acknowledge the potential of AMZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off-the-shelf' T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here. Second Quarter 2025 Business Update Highlights On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1. Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch. Strong support from leading clinical experts and sites; refined trial design and moving to operational readiness ahead of IND/CTA submission Financial highlights Total operating expenses amounted to MNOK 38.4 in Q2 2025, and MNOK 67.8 YTD. Total loss was MNOK 37.5 for the period and MNOK 66.0 YTD. Net negative cash flow from operations was MNOK 59.4 in Q2 2025, and net decrease in cash and cash equivalents, excluding currency effects, was MNOK 59.0 during Q2 2025. Cash and cash equivalents amounted to MNOK 76.0 as per 30 June 2025. The current cash is expected to give a financial runway into Q2 2026, slightly shortened from the previously guided 'through Q2 2026' due to some one-off cost elements mainly related to investment in the successful development of the TCR-NK manufacturing process. The expected financial runway reflects that the cash burn rate is forecasted to come down significantly from the Q2 2025 level. On 27 May 2025, Zelluna ASA issued 227,096 new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The quarterly report and presentation will be published at 07:00 CET on 20 August 2025, and will be publicly available on the Zelluna website. The Company will conduct a webcast at 09:00 CET the same day, and questions can be submitted throughout the event. The webcast will be archived for replay following the conference call. Link to webcast here. For further information, please see or contact: Namir Hassan, CEO, Zelluna ASAEmail: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASAEmail: +47 482 48632 About Zelluna ASA Zelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of 'off-the-shelf' T-cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used 'off-the-shelf' to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting 'off-the-shelf' TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through clinical development of TCR and cell-based therapies including marketed products. For more information, please visit This stock exchange announcement was published by Joachim Midttun, Financial Manager at Zelluna ASA, on 20 August 2025 at 07:00 CET. Attachments Zelluna-ASA-Q225-Report Zelluna-ASA-Q225-Presentation
